ChemoCentryx Newswire

ChemoCentryx Newswire

Comprehensive Real-Time News Feed for ChemoCentryx.

Results 1 - 20 of 46 in ChemoCentryx

  1. Positive Results From ChemoCentryx, Inc. Phase II Diabetic...Read the original story

    Thursday May 28 | BioSpace

    Positive Results From ChemoCentryx, Inc. Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At The 52nd ERA-EDTA Congress -- Significant reduction in proteinuria over 52 weeks of treatment suggests CCX140 may have renoprotective effects exceeding current standard of care alone -- -- Separately, poster describing anti-thrombogenic potential of complement C5a receptor inhibitor CCX168 in serum from patients with atypical hemolytic uremic syndrome to be presented -- MOUNTAIN VIEW, Calif., May 28, 2015 -- ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced data presentations from two of its chemoattractant receptor programs, CCR2 and C5aR, at the 52nd European Renal Association - European Dialysis and Transplant Association Congress being held May 28 to ... (more)

    Comment?

  2. Insider Selling: Ira Klein Sells 10,811 Shares of ChemoCentryx StockRead the original story

    Tuesday May 26 | AmericanBankingNews.com

    ChemoCentryx Director Ira Klein sold 10,811 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $7.44, for a total transaction of $80,433.84.

    Comment?

  3. Psoriasis Therapeutic Pipeline Review, H1 2015Read the original story

    Tuesday May 26 | Emailwire.com

    ... Brickell Biotech, Inc., Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., ChironWells GmbH, Circassia Pharmaceuticals plc, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., ...

    Comment?

  4. Positive Clinical Data From ChemoCentryx, Inc. Phase II Trial In...Read the original story

    Monday May 25 | BioSpace

    ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2, has been selected for an oral presentation in the Late Breaking Clinical Trial session at the 52nd Annual European Renal Association-European Dialysis and Transplant Association Congress being held May 28 to 31 in London, UK. The Company's CCX140 Phase II clinical trial was conducted at multiple study centers across six European countries and enrolled patients with diabetic nephropathy for a 52-week treatment period.

    Comment?

  5. Psoriasis - Pipeline Review, H1 2015: New research report available at Fast Market ResearchRead the original story

    Monday May 18 | PR-inside.com

    ... Brickell Biotech, Inc., Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., ChironWells GmbH, Circassia Pharmaceuticals plc, Coherus BioSciences, Inc., Compugen Ltd.,

    Comment?

  6. ChemoCentryx, Inc. Reports First Quarter 2015 Financial Results And Provides Corporate UpdateRead the original story

    Wednesday May 6 | BioSpace

    Accelerated enrollment in CCX168 European Phase II CLEAR trial in patients with AAV projects top-line results by the end of 2015 -- -- CCX140 diabetic nephropathy results selected as a "late breaking" oral presentation at the 52nd ERA-EDTA Congress on May 29, 2015 -- MOUNTAIN VIEW, Calif., May 6, 2015 -- ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported financial results for the first quarter ended March 31, 2015 and provided an update on the Company's corporate and clinical development activities.

    Comment?

  7. ChemoCentryx's (CCXI) CEO Thomas Schall on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Wednesday May 6 | Seeking Alpha

    Welcome to the ChemoCentryx First Quarter 2015 Financial Results Conference Call. [Operator Instructions].

    Comment?

  8. Global Inflammatory Bowel Disease Market 2015-2019 - Worldwide...Read the original story

    Monday May 4 | Emailwire.com

    ... A* Shire A* UCB Other Prominent Vendors A* Amgen A* Akebia Therapeutics A* Boehringer Ingelheim A* Celltrion A* ChemoCentryx A* Ferring Pharmaceuticals A* Galapagos A* Genentech A* Merck A* Mitsubishi Tanabe A* Novartis A* Novo Nordisk A* Pfizer A* ...

    Comment?

  9. Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019.Read the original story w/Photo

    Apr 28, 2015 | PR-inside.com

    ... UCB SA. Other Prominent Vendors in the market are: Amgen, Akebia Therapeutics, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Galapagos, Genentech, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer and Salix Pharmaceuticals. ...

    Comment?

  10. ChemoCentryx, Inc. To Hold First Quarter 2015 Financial Results...Read the original story

    Apr 21, 2015 | BioSpace

    ChemoCentryx, Inc. announced today that the Company's first quarter 2015 financial results will be released after market close on Wednesday, May 6, 2015. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on May 6, 2015, to discuss these results and to answer questions.

    Comment?

  11. ChemoCentryx Initiates Clinical Trial of Its Next-Generation CCR2 Inhibitor in Pancreatic CancerRead the original story w/Photo

    Apr 20, 2015 | Pharmaceutical Processing

    ChemoCentryx, Inc, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced the commencement of patient enrollment in a Phase Ib clinical trial with CCX872, in patients with non-resectable pancreatic cancer. CCX872 is the company's second clinical compound which is an orally administered inhibitor of the chemokine receptor known as CCR2.

    Comment?

  12. ChemoCentryx, Inc. Initiates Clinical Trial Of CCX872, Its...Read the original story

    Apr 19, 2015 | BioSpace

    ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced the commencement of patient enrollment in a Phase Ib clinical trial with CCX872, in patients with non-resectable pancreatic cancer. CCX872 is the Company's second clinical compound which is an orally administered inhibitor of the chemokine receptor known as CCR2.

    Comment?

  13. Global Inflammatory Bowel Disease Market 2019 - Increase in Patient...Read the original story

    Apr 19, 2015 | Emailwire.com

    ... Merck & Company Shire UCB Other Prominent Vendors Amgen Akebia Therapeutics Boehringer Ingelheim Celltrion ChemoCentryx Ferring Pharmaceuticals Galapagos Genentech Merck Mitsubishi Tanabe Novartis Novo Nordisk Pfizer Salix Pharmaceuticals Inquire ...

    Comment?

  14. Therapy Focus - Beyond Blood Pressure Control For IgA NephropathyRead the original story w/Photo

    Apr 16, 2015 | Seeking Alpha

    ... arthritis, is being tested in 75 patients in a placebo-controlled trial expected to read out next year. ChemoCentryx 's (NASDAQ: CCXI ) CCX168 is also an immunosuppressive agent, and like the rest of that group's pipeline acts on immune signalling ...

    Comment?

  15. Glomerulonephritis - Pipeline Review, H1 2015 - New Market Study PublishedRead the original story

    Apr 12, 2015 | PR-inside.com

    ... in this Report: Adienne Pharma & Biotech, Alexion Pharmaceuticals, Inc., Avexxin AS, Biogen Idec Inc., ChemoCentryx, Inc., FibroStatin SL, GlaxoSmithKline plc, Hansa Medical AB, Mallinckrodt plc, New Zealand Pharmaceuticals Limited, Pharmalink AB, ...

    Comment?

  16. ChemoCentryx CEO Sells $9,012.00 in StockRead the original story

    Apr 1, 2015 | AmericanBankingNews.com

    ChemoCentryx CEO Thomas J. Schall sold 1,200 shares of the stock on the open market in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $7.51, for a total transaction of $9,012.00.

    Comment?

  17. ChemoCentryx CEO Sells $394,908.64 in StockRead the original story

    Mar 24, 2015 | AmericanBankingNews.com

    ChemoCentryx CEO Thomas J. Schall sold 50,371 shares of the stock on the open market in a transaction that occurred on Tuesday, March 24th. The stock was sold at an average price of $7.84, for a total value of $394,908.64.

    Comment?

  18. Global CrohnA's Disease (CD) Market Research Report 2019Read the original story

    Mar 15, 2015 | Emailwire.com

    ... Idec Johnson & Johnson Takeda Pharmaceutical UCB Other Prominent Vendors Amgen Boehringer Ingelheim Celltrion ChemoCentryx Ferring Pharmaceuticals Merck Mitsubishi Tanabe Novartis Novo Nordisk Pfizer Inquire Before Buying @ ...

    Comment?

  19. ChemoCentryx, Inc. Reports Fourth Quarter 2014 Financial Results And Provides Corporate UpdateRead the original story

    Mar 12, 2015 | BioSpace

    Recruitment projections to complete enrollment in C5aR inhibitor CCX168 CLEAR Phase II ANCA-associated vasculitis clinical trial remain on track -- -- Initial data anticipated from other pipeline programs, including CCX168 in atypical Hemolytic Uremic Syndrome, CCX872 in non-resectable pancreatic cancer, and other pipeline programs -- MOUNTAIN VIEW, Calif., March 12, 2015 -- ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported financial results for the fourth quarter ended December 31, 2014 and provided an update on the Company's corporate and clinical development activities expected in 2015.

    Comment?

  20. Global CD market to grow at a CAGR of 2.84 percent over the period 2014-2019.Read the original story w/Photo

    Mar 12, 2015 | PR-inside.com

    ... Co. Ltd. and UCB SA Other Prominent Vendors in the market are: Amgen, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Merck, Mitsubishi Tanabe, Novartis, Novo Nordisk and Pfizer. An increase in strategic collaborations is one ...

    Comment?